Showing 1,321 - 1,340 results of 63,109 for search '(( 50 ((mean decrease) OR (a decrease)) ) OR ( 5 ((nm decrease) OR (we decrease)) ))', query time: 1.23s Refine Results
  1. 1321
  2. 1322
  3. 1323
  4. 1324
  5. 1325
  6. 1326
  7. 1327

    The prevalence of hypertension, diabetes, metabolic syndrome, cardiovascular disease and decreased GFR according to the following age groups: 60–69, 70–79 and ≥80 years. by Regina C. R. M. Abdulkader (302450)

    Published 2017
    “…Metabolic syndrome: presence of at least three of the following criteria: a waist circumference ≥90 cm for men or ≥80 cm for women, triglycerides ≥150 mg/dL, an HDL cholesterol ≤40 mg/dL for males or ≤50 mg/dL for females, a systolic blood pressure ≥130 mm Hg or a diastolic blood pressure ≥85 mmHg and a fasting plasma glucose ≥100 mg/dL. …”
  8. 1328
  9. 1329
  10. 1330
  11. 1331
  12. 1332
  13. 1333
  14. 1334
  15. 1335

    Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  16. 1336

    Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

    Published 2022
    “…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”
  17. 1337

    Image_3_A Shift in Myeloid Cell Phenotype via Down Regulation of Siglec-1 in Island Macrophages of Bone Marrow Is Associated With Decreased Late Erythroblasts Seen in Anemia of Cri... by Shirin Hasan (7894118)

    Published 2019
    “…There was only a marginal increase in the number of EBIMØ after burn, but, between the signatures of EBIMØ, Siglec-1 expression (MFI) was reduced by 40% in B with and a parallel 44% decrease in TBM erythrons in the BM. There were more (2.5-fold) EEBs and less LEBs (2.4-fold) per million TBM cells in B; with a corresponding decrease in Siglec-1 and Ly6G expressions in EBIMØ associated with EEB. …”
  18. 1338

    Image_4_A Shift in Myeloid Cell Phenotype via Down Regulation of Siglec-1 in Island Macrophages of Bone Marrow Is Associated With Decreased Late Erythroblasts Seen in Anemia of Cri... by Shirin Hasan (7894118)

    Published 2019
    “…There was only a marginal increase in the number of EBIMØ after burn, but, between the signatures of EBIMØ, Siglec-1 expression (MFI) was reduced by 40% in B with and a parallel 44% decrease in TBM erythrons in the BM. There were more (2.5-fold) EEBs and less LEBs (2.4-fold) per million TBM cells in B; with a corresponding decrease in Siglec-1 and Ly6G expressions in EBIMØ associated with EEB. …”
  19. 1339
  20. 1340

    BpiB09 affects the QS-dependent pyocyanin production, <i>C. elegans</i> paralysis in PAO1 and decreases AHL response in <i>A. tumefaciens</i> AHL reporter strain. by Patrick Bijtenhoorn (199146)

    Published 2011
    “…<p><b>A</b>) Decreased pyocyanin production. OD<sub>520</sub> of pyocyanin extracts from culture supernatants of <i>P. aeruginosa</i> carrying pBBR1MCS-5::<i>bpiB09</i> and empty pBBR1MCS-5. …”